Cellectis SA
PAR:ALCLS

Watchlist Manager
Cellectis SA Logo
Cellectis SA
PAR:ALCLS
Watchlist
Price: 4.11 EUR -10.07% Market Closed
Market Cap: 296.3m EUR

Operating Margin
Cellectis SA

-45.6%
Current
-394%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-45.6%
=
Operating Profit
-51.4m
/
Revenue
112.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Cellectis SA
PAR:ALCLS
297.3m EUR
-46%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
394.7B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.9B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD
28%
AU
CSL Ltd
ASX:CSL
89.1B AUD
26%
NL
argenx SE
XBRU:ARGX
45.9B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD
8%
No Stocks Found

Cellectis SA
Glance View

Market Cap
297.3m EUR
Industry
Biotechnology

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

ALCLS Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-45.6%
=
Operating Profit
-51.4m
/
Revenue
112.6m
What is the Operating Margin of Cellectis SA?

Based on Cellectis SA's most recent financial statements, the company has Operating Margin of -45.6%.

Back to Top